ES2482342A1 - TRATAMIENTO TERAPÉUTICO DE LEUCEMIAS LINFOBLÁSTICAS AGUDAS T y B Y LINFOMAS HUMANOS POR INHIBICIÓN DEL RECEPTOR DE INTERLEUQUINA-7 (IL-7R) - Google Patents

TRATAMIENTO TERAPÉUTICO DE LEUCEMIAS LINFOBLÁSTICAS AGUDAS T y B Y LINFOMAS HUMANOS POR INHIBICIÓN DEL RECEPTOR DE INTERLEUQUINA-7 (IL-7R) Download PDF

Info

Publication number
ES2482342A1
ES2482342A1 ES201232037A ES201232037A ES2482342A1 ES 2482342 A1 ES2482342 A1 ES 2482342A1 ES 201232037 A ES201232037 A ES 201232037A ES 201232037 A ES201232037 A ES 201232037A ES 2482342 A1 ES2482342 A1 ES 2482342A1
Authority
ES
Spain
Prior art keywords
human
receptor
interleukin
inhibition
lymphoblastic leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201232037A
Other languages
English (en)
Other versions
ES2482342B1 (es
Inventor
María Luisa TORIBIO GARCÍA
Sara GONZÁLEZ GARCÍA
Marina GARCÍA PEYDRÓ
Juan ALCAIN SÁNCHEZ
Patricia FUENTES VILLAREJO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Priority to ES201232037A priority Critical patent/ES2482342B1/es
Priority to PCT/ES2013/070923 priority patent/WO2014102430A1/es
Publication of ES2482342A1 publication Critical patent/ES2482342A1/es
Application granted granted Critical
Publication of ES2482342B1 publication Critical patent/ES2482342B1/es
Withdrawn - After Issue legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere al tratamiento terapéutico de leucemias linfoblásticas agudas (LLA) humanas de células T y B (LLA-T y LLA-B) y linfomas humanos, por inhibición del receptor de interleuquina-7 (IL-7R) humana. Un primer aspecto de la presente invención es un agente inhibidor o bloqueante, preferentemente un anticuerpo o un fragmento del mismo, capaz de bloquear la función de la cadena α del receptor de interleuquina 7 (IL-7Rα) humano, para la prevención y/o el tratamiento de una LLA humana o de un linfoma humano. Asimismo, la presente invención hace referencia a una composición farmacéutica y a un modelo de identificación, expansión y mantenimiento in vivo de células iniciadoras de LLA-T y LLA-B primarias humanas con capacidad de iniciar el injerto de la leucemia en ratones inmunodeficientes, así como la caracterización de estas células iniciadoras de LLA-T y LLA-B como células que expresan altos niveles del IL-7R.

Description

.
ES201232037A 2012-12-27 2012-12-27 TRATAMIENTO TERAPÉUTICO DE LEUCEMIAS LINFOBLÁSTICAS AGUDAS T y B Y LINFOMAS HUMANOS POR INHIBICIÓN DEL RECEPTOR DE INTERLEUQUINA-7 (IL-7R) Withdrawn - After Issue ES2482342B1 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES201232037A ES2482342B1 (es) 2012-12-27 2012-12-27 TRATAMIENTO TERAPÉUTICO DE LEUCEMIAS LINFOBLÁSTICAS AGUDAS T y B Y LINFOMAS HUMANOS POR INHIBICIÓN DEL RECEPTOR DE INTERLEUQUINA-7 (IL-7R)
PCT/ES2013/070923 WO2014102430A1 (es) 2012-12-27 2013-12-24 TRATAMIENTO TERAPÉUTICO DE LEUCEMIAS LINFOBLÁSTICAS AGUDAS T y B Y LINFOMAS HUMANOS POR INHIBICIÓN DEL RECEPTOR DE INTERLEUQUINA-7 (IL-7R)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201232037A ES2482342B1 (es) 2012-12-27 2012-12-27 TRATAMIENTO TERAPÉUTICO DE LEUCEMIAS LINFOBLÁSTICAS AGUDAS T y B Y LINFOMAS HUMANOS POR INHIBICIÓN DEL RECEPTOR DE INTERLEUQUINA-7 (IL-7R)

Publications (2)

Publication Number Publication Date
ES2482342A1 true ES2482342A1 (es) 2014-08-01
ES2482342B1 ES2482342B1 (es) 2015-07-02

Family

ID=51019933

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201232037A Withdrawn - After Issue ES2482342B1 (es) 2012-12-27 2012-12-27 TRATAMIENTO TERAPÉUTICO DE LEUCEMIAS LINFOBLÁSTICAS AGUDAS T y B Y LINFOMAS HUMANOS POR INHIBICIÓN DEL RECEPTOR DE INTERLEUQUINA-7 (IL-7R)

Country Status (2)

Country Link
ES (1) ES2482342B1 (es)
WO (1) WO2014102430A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017062748A1 (en) 2015-10-07 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
WO2020077190A1 (en) * 2018-10-12 2020-04-16 Jumaa Weinacht Hassan Monoclonal antibody for treating acute lymphoblastic leukemia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006306817A (ja) * 2005-04-28 2006-11-09 Tokyo Univ Of Science プレｂ細胞急性リンパ性白血病治療剤及び治療方法、細胞増殖抑制剤、プレｂ細胞急性リンパ性白血病モデルマウス、並びにプレｂ白血病細胞株
EP2583980A1 (en) * 2011-10-19 2013-04-24 Effimune Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates

Also Published As

Publication number Publication date
ES2482342B1 (es) 2015-07-02
WO2014102430A1 (es) 2014-07-03

Similar Documents

Publication Publication Date Title
PH12016501171A1 (en) Peptidomimetic compounds and antibody-drug conjugates thereof
UA110213C2 (en) Use of sigma-ligand induced opioid hyperalgesia
MX371344B (es) Antagonistas de il-4r para usarse en el tratamiento o prevención de asma persistente y asma severa.
UA106634C2 (uk) Тверда фармацевтична дозована форма
IN2012DN02735A (es)
IN2012DN02702A (es)
IN2012DN00754A (es)
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
PH12017500453B1 (en) Spirocyclic inhibitors of cathepsin c
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
MX2018000419A (es) Derivados de amida sustituida que tienen actividad multimodal contra el dolor.
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
IN2012DN02471A (es)
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
PH12016502353A1 (en) Pharmaceutical composition
GEP20166450B (en) Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same
MX2016006604A (es) Derivados de piperidina con actividad multimodal contra el dolor.
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
TN2012000610A1 (en) Heterocyclic compounds, their preparation and their therapeutic application
EA201791227A1 (ru) РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM
GB2492037A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX2021001786A (es) Antagonistas de integrina.
MX2016006603A (es) Compuestos piperidinicos con actividad multimodal contra el dolor.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2482342

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20150702

FA2A Application withdrawn

Effective date: 20151102